{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:00:04Z","timestamp":1775545204720,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016819","name":"Octapharma","doi-asserted-by":"publisher","award":["IS-II-DE-02"],"award-info":[{"award-number":["IS-II-DE-02"]}],"id":[{"id":"10.13039\/100016819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009431","name":"Baxalta","doi-asserted-by":"publisher","award":["IIR-DEU-001589"],"award-info":[{"award-number":["IIR-DEU-001589"]}],"id":[{"id":"10.13039\/100009431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Infections are a major cause of early morbidity and mortality in patients with multiple myeloma (MM) who are characterized by immunodeficiency secondary to disease. However, prospectively collected data on infection risk in this population are scarce. We aimed at identifying parameters in monoclonal gammopathy of undetermined significance (MGUS) and newly diagnosed MM (NDMM) patients with predictive power for early severe infections (SI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective study with newly diagnosed MGUS and NDMM patients. Besides clinical and laboratory data, immune parameters were collected at initial diagnosis before therapy initiation. Primary endpoint was the occurrence of SI within 12 months after diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>45% of patients developed infection, 26% with SI. Four main risk factors for SI were identified: ECOG \u2265 2 (p &amp;lt; 0.001), ISS stage II\/III (p = 0.002), therapeutic intervention (p &amp;lt; 0.001), and elevated CD8<jats:sup>+<\/jats:sup> TEMRA cells (p = 0.027). A risk score was compiled, enabling the stratification of patients with low or high risk for SI with a sensitivity of 92.9% and a specificity of 80%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed a straightforward risk score that considers the relevance of T cell fitness in MGUS and NDMM patients and can help physicians to identify patients at risk of infection, thus enabling the implementation of timely and individualized prevention strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1532645","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:59:11Z","timestamp":1739357951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced disease and CD8+ TEMRA cells predict severe infections in multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Eva","family":"Tranter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarissa","family":"Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nogai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Schiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Frentsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il-Kang","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.blre.2022.101020","article-title":"Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel","volume":"58","author":"Jolles","year":"2023","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.12703\/r\/11-34","article-title":"Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond","volume":"11","author":"Abeykoon","year":"2022","journal-title":"Fac Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/BF00915255","article-title":"Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function","volume":"6","author":"Pilarski","year":"1986","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00609.x","article-title":"T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486\/E3A93: T-helper Cells in Untreated and Treated Myeloma Patients","volume":"100","author":"Kay","year":"1998","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Sch\u00fctt","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.340.340_340_345","article-title":"Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial","volume":"90","author":"Kay","year":"1997","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients","volume":"98","author":"Kay","year":"2001","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.736137","article-title":"CD4+ T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation","author":"Heck","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16235","article-title":"Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ying","year":"2017","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.2019.102.issue-2","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig","year":"2019","journal-title":"Eur J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13066","article-title":"Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark","volume":"101","author":"S\u00f8rrig","year":"2018","journal-title":"Eur J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.772015","article-title":"Development of a risk assessment model for early grade \u2265 3 infection during the first 3 months in patients newly diagnosed with multiple myeloma based on a multicenter, real-world analysis in China","volume":"12","author":"Shang","year":"2022","journal-title":"Front Oncol"},{"key":"B15","article-title":"Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients","author":"Mai","year":"2023","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade \u2265 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24796","article-title":"Recognition of early mortality in multiple myeloma by a prediction matrix: TEREBELO et\u00a0al","volume":"92","author":"Terebelo","year":"2017","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2015.03.023","article-title":"Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP","volume":"283","author":"Klehmet","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002\u2014Medical research council adult leukaemia working party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00257\/abstract","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma","author":"Tete","year":"2014","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.04.010","article-title":"Risk and severity of COVID-19 infection in monoclonal gammopathy of undetermined significance: A 3-year propensity matched cohort study","volume":"23","author":"Ashruf","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1182\/blood.2022017616","article-title":"Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"Van De Donk","year":"2014","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-379","article-title":"Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections","volume":"8","author":"Appay","year":"2002","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3577","article-title":"Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines","volume":"101","author":"Geginat","year":"2003","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13073-021-00918-7","article-title":"Maintenance of the human memory T cell repertoire by subset and tissue site","volume":"13","author":"Miron","year":"2021","journal-title":"Genome Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27804","article-title":"Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity","volume":"116","author":"Cornberg","year":"2006","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic Malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1532645\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:59:15Z","timestamp":1739357955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1532645\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1532645"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1532645","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"1532645"}}